{"id":"0003cffb-baea-48e5-b3a7-e425a4f80bd2","arxiv_id":"2507.03186","paper_version":1,"verdict":"CONDITIONAL","confidence":"MODERATE","novelty_score":6.0,"correctness_risk":"low","formal_verification":"none","parameter_count":3,"one_line_summary":"In vivo synchrotron micro-CT achieves whole-brain, micrometer-voxel imaging of mouse cerebrospinal fluid spaces, enabling quantitative tracking of contrast agent distribution and tissue motion.","lead":"This paper demonstrates a new way to image the living mouse brain: synchrotron X-ray micro-CT captures the whole brain at micrometer-scale voxel size and tracks cerebrospinal fluid movement and tissue motion over time. It fills a resolution and field-of-view gap between two-photon microscopy and MRI, which may help validate models of how fluid moves through the brain.","discovery_kind":"new_application","skeptic_critique":{"model":"deepseek-v4-flash","headline":"The 6.3 µm 'whole-brain' claim conflicts with the stated detector FOV (16.1×4.9 mm), which is vertically too short for the adult mouse brain; the whole-brain claim appears to hold only for the 8 µm dataset.","rationale":"Read in good faith, the paper is a methods/feasibility study: it demonstrates that intravital SRµCT can image mouse CNS fluid spaces with roughly 10 µm/10 s resolution and a whole-brain field of view, bridging multiphoton microscopy and MRI. The load-bearing condition for the central claim is that the touted micrometer-resolution acquisition actually covers the entire brain. The methods for the 6.3 µm scan (Mouse19) give a detector FOV of 16.1 mm × 4.9 mm, and 4.9 mm is less than the ~5.5–6.5 mm dorsoventral height of an adult C57BL/6 mouse brain; no stitching is described. Thus the abstract's 'whole-brain imaging at 6.3 µm' is, on its face, geometrically unsupported. The 8 µm SPring-8 scan plausibly covers the whole brain, so the method's core contribution may survive, but the specific quantitative claim in the abstract and results needs correction or additional evidence. I consider this more load-bearing than the reader's physiology-perturbation concern: the latter affects the interpretation of the dynamic solute measurements, whereas the FOV mismatch directly contradicts a central quantitative claim and is immediately checkable from the released data. The paper has real strengths—multi-facility validation, open code and hardware, careful FSC resolution estimates, and a clear peri-mortem demonstration of why in vivo imaging matters—none of which are in dispute. The recommended verdict is CONDITIONAL: the authors should either demonstrate (or document) that the 6.3 µm acquisition covers the entire brain via tiling, or revise the claim to specify the actual volume coverage. The reader's identified anesthesia/infusion concern is legitimate but, in my assessment, secondary to the FOV discrepancy when judging the central claim.","tokens_in":31323,"tokens_out":10877,"duration_ms":126214,"concrete_test":"Access the Zenodo repository (doi:10.5281/zenodo.13773080), open the reconstructed 3D volume for SubjectID Mouse19, and compute the z-extent: number of slices × 6.3 µm. Compare with the dorsoventral span of the mouse brain in the same orientation (e.g., using the included skull/brain masks or the Allen reference atlas). Check whether the stack contains both dorsal cortex and ventral brainstem. If the z-extent is ≈4.9 mm, the 'whole-brain at 6.3 µm' claim is false; if the stack is taller (e.g., via undocumented stitching), the claim stands. This single check settles whether the abstract's key quantitative claim is accurate.","verdict_should_be":"CONDITIONAL","load_bearing_attack":"The central claim (Abstract; Results 'Anatomic imaging at cellular resolution and whole-organ field of view') is that whole-brain imaging at 6.3 µm uniform voxel size was achieved. However, the Methods for the native-state ESRF ID17 acquisition (SubjectID Mouse19, pixel size 6.3 µm) specify an effective field of view of 2560 × 780 pixels, i.e. 16.1 mm × 4.9 mm. The vertical extent of this FOV (4.9 mm) is smaller than the typical dorsoventral extent of the adult C57BL/6 mouse brain (≈5.5–6.5 mm; e.g., Allen Mouse Brain Atlas). No vertical tiling or multi-scan stitching is described for this acquisition. The 8.0 µm SPring-8 scan (JP28) has a 16.4 × 12.0 mm FOV and can plausibly cover the whole brain, but the 6.3 µm claim is not supported by the stated geometry. The dynamic time series (Mouse63, Mouse50) at 6.45 µm voxels have even smaller vertical FOVs (16.5 × 4.5 mm), so those are also not whole-brain. If the 6.3 µm volume is only a 4.9 mm slab, then the abstract's headline capability—whole-organ field of view at micrometer resolution—is demonstrated only at 8 µm, and 'whole-brain at 6.3 µm' must be revised or supported with documented stitching. This is a data-checkable factual inconsistency rather than an interpretive question about anesthesia or infusion effects.","agreement_with_reader":"disagree"},"referee_report":{"model":"deepseek-v4-flash","summary":"The paper presents a method for in vivo synchrotron radiation-based micro computed tomography (SRμCT) of mouse CNS fluid spaces, built around a portable holder and life-support system deployed at three synchrotron facilities. It demonstrates native-state and contrast-enhanced whole-organ imaging, quantitative mapping of a barium nanoparticle contrast agent over time, peri-mortem ventricular shrinkage, and motion quantification via retrospective cardiac gating and non-gated time series. The authors report whole-brain imaging at 6.3 μm voxel size and dynamic imaging with scan times of 10–32 s, positioning SRμCT as a bridge between multiphoton microscopy and MRI for mouse brain studies.","tokens_in":31646,"tokens_out":9789,"duration_ms":104750,"significance":"If the technical claims hold, SRμCT fills a genuine gap: no other modality currently offers micrometer-scale resolution and whole-organ coverage in the living mouse brain. The paper's strengths include multi-facility validation, openly shared hardware designs and code, calibrated attenuation-to-concentration mapping, FSC-based resolution estimation, and a clear description of the peri-mortem changes that motivate in vivo imaging. These are concrete, reproducible contributions. The main weakness is that the headline 'whole-brain at 6.3 μm' claim is not supported by the reported detector fields of view, and the physiological interpretation of post-infusion solute dynamics rests on unverified assumptions about the preparation's fidelity to native CSF physiology.","major_comments":[{"comment":"The claim of whole-brain imaging at 6.3 μm uniform voxel size is contradicted by the stated geometry. The 6.3 μm acquisition (Mouse19) has an effective field of view of 2560 × 780 pixels, i.e., 16.1 mm × 4.9 mm, and the dynamic 6.45 μm acquisitions (Mouse63, Mouse50) have fields of view of 2560 × 700 pixels, i.e., 16.5 mm × 4.5 mm. These vertical extents are smaller than the typical dorsoventral extent of the adult mouse brain (≈5.5–6.5 mm), and no vertical tiling or stitching is described for any of these scans. The only dataset whose field of view plausibly covers the whole brain is the 8.0 μm SPring-8 acquisition (JP28, 16.4 mm × 12.0 mm). The abstract, the Results section, and the Discussion therefore overstate the demonstrated coverage: whole-brain coverage at micrometer resolution is shown at 8 μm, while the 6.3–6.45 μm acquisitions cover only a sub-volume of the brain. Please revise the claims to state that whole-brain coverage is demonstrated at 8.0 μm, or document how the 6.3 μm volume covers the entire brain (e.g., with explicit stitching details).","section":"Abstract; Results 'Anatomic imaging...'; Methods 'Native-state imaging at ESRF ID17'; Supplementary Table 1"},{"comment":"The manuscript interprets the post-infusion contrast agent distribution as governed by 'the natural interplay of diffusion and convection' (Results) and uses this to argue that SRμCT provides unique data on CSF dynamics. However, the infused volumes (1–5.75 μl) are comparable to or larger than the cited mouse CSF production rate (0.3–0.7 μl/min), and intracranial pressure is not monitored. During the infusion phase the authors correctly attribute transport to the infusion pump, but the post-infusion phase is presented without direct evidence that the preparation does not substantially alter CSF volume, pressure, or flow. To support the 'natural' interpretation, the paper should either provide ICP measurements or a sham-infusion control, or explicitly soften the language to describe solute distribution under the conditions of this anesthetized, ventilated, and infused preparation rather than as unperturbed physiology.","section":"Results 'Mapping spatiotemporal solute distribution...'; Methods 'Intra-cerebroventricular infusion at ESRF ID17'"}],"minor_comments":[{"comment":"The infusion rate and volume for Mouse63 and Mouse50 appear to be swapped: Supplementary Table 1 lists Mouse63 as 0.5 μl/min and 2.5 μl and Mouse50 as 0.2 μl/min and 1 μl, whereas the Methods text states that the intra-cerebroventricular infusion (Mouse63) used 0.2 μl/min for 1 μl and the intra-cisterna magna infusion (Mouse50) used 0.5 μl/min for 2.5 μl.","section":"Supplementary Table 1"},{"comment":"The sentence describing the FSC threshold cites reference 53 (Rudick et al., 1982), a CSF clearance study, rather than the FSC methodology reference (van Heel & Schatz, reference 57), and the Savitzky-Golay filter 'window width of 5088' appears to be a typographical error. Please correct the citation and the filter width.","section":"Methods, FSC paragraph under 'Intra-cerebroventricular infusion at ESRF ID17'"},{"comment":"The text reports '2 188 projections per bin' for 18 bins, which sums to approximately 39,400 projections, not the stated 60,000 total acquisitions; please clarify whether some projections were excluded (e.g., outside the minimum cycle duration) or correct the arithmetic.","section":"Methods, 'Retrospective cardiac-gated imaging at ESRF ID17'"},{"comment":"Each quantitative demonstration (e.g., Mouse63 for ICV dynamics, Mouse50 for ICM, CA019 for choroid plexus motion, JP34 for peri-mortem shrinkage) is based on a single animal. This is acceptable for a proof-of-principle methods paper, but the manuscript should state explicitly that these are n=1 demonstrations and should not be interpreted as population-level results.","section":"Discussion and Methods"}],"recommendation":"major_revision","confidential_remarks":"The paper is a strong technical contribution with open data and code, and the central feasibility claim is likely correct. The main obstacle is the unsupported 'whole-brain at 6.3 μm' claim, which is a straightforward fix: either revise the abstract and results to state that whole-brain coverage is demonstrated at 8 μm, or document stitching for the 6.3 μm datasets. The physiological interpretation concern is more substantive but can be addressed by softening the language and adding explicit limitations. I recommend major revision rather than rejection, as the core method appears sound and the identified issues are correctable within the manuscript's scope."},"author_rebuttal":null,"desk_editor":{"model":"deepseek-v4-flash","letter":"The core of this paper is the engineering, and that part is solid: a portable, openly documented in vivo SRμCT setup for mouse CNS fluid spaces, demonstrated at three synchrotrons, with 10–32 s scans, quantitative barium concentration mapping, cardiac-gated motion analysis, and time-series CSF distribution data. The peri-mortem ventricular shrinkage data are a useful caution about interpreting ex vivo anatomy. Code, hardware designs, and reconstructed data are available. The citation pattern looks appropriate; prior in vivo SRuCT work is cited, and the self-citations are for gating and setup components, not for the central claim.\n\nThe soft spots are real but mostly fixable. The biggest one: the abstract claims whole-brain imaging at 6.3 μm uniform voxel size, and the Results repeat that. But the 6.3 μm datasets (Mouse19, Mouse17) were acquired with an effective FOV of 16.1 × 4.9 mm, and no tiling or stitching is described. That vertical extent is too short for the adult C57BL/6 mouse brain, which runs roughly 5.5–6.5 mm dorsoventrally. The dynamic time series at 6.45 μm are even smaller vertically (16.5 × 4.5 mm). The 8 μm SPring-8 dataset, with a 16.4 × 12.0 mm FOV, plausibly covers the whole brain. So the whole-brain capability is demonstrated at 8 μm, not at 6.3 μm. This is a factual inconsistency, not an interpretive disagreement; it needs a wording fix or documented stitching. I checked the stress-test concern against the paper and it holds.\n\nThe other weaknesses are the ones the reader flagged: single animals per experiment, manual segmentation choices, and no ground truth for the tissue motion. Those are acceptable for a feasibility methods paper if the claims are framed as demonstrations, which they mostly are, but the quantitative numbers (ventricular shrinkage percentages, choroid plexus displacement medians) should not be read as population benchmarks. The anesthesia/ventilation/infusion preparation is another soft spot: the paper interprets post-infusion solute dynamics as natural diffusion and convection, yet intracranial pressure was not monitored and the preparation's effect on CSF volume and flow is not validated. That is a limitation to state explicitly, not a fatal flaw.\n\nThe Paganin δ/β = 200 tuning is acknowledged as non-physical, which is honest. FSC resolution estimates are reasonable for this kind of data.\n\nWho is this for? Researchers working on CSF dynamics, solute transport, and brain imaging methods. They will get real utility from the setup description and the feasibility data. This paper deserves a serious referee: I would send it out, with instructions to check the whole-brain/FOV claim carefully and to ask for either corrected claims or stitching evidence. With that revision, it becomes a solid methods contribution.","headline":"The in vivo SRμCT method is real and worth refereeing, but the abstract's 'whole-brain at 6.3 μm' claim is not supported by the stated detector field of view; the whole-brain demonstration is at 8 μm.","tokens_in":32360,"tokens_out":2120,"would_cite":true,"duration_ms":27686,"reading_group":"yes","serious_thinker":"yes","would_accept_peer_review":true},"rs_alignment":null,"lean_confirmation":null,"pith_extraction":{"msc":[],"pacs":[],"model":"deepseek-v4-flash","headline":"Intravital synchrotron micro-CT achieves whole-brain imaging of mouse CSF spaces at 6.3 µm resolution in 10-second scans.","keywords":["synchrotron radiation micro computed tomography","in vivo imaging","mouse brain","cerebrospinal fluid dynamics","contrast agent quantification","retrospective cardiac gating","peri-mortem ventricular shrinkage","choroid plexus motion"],"falsifier":"Measure intracranial pressure continuously during and after a lateral-ventricle infusion of 1–5.75 µl at the rates used here; if CSF pressure rises substantially above the physiological range or ventricular volume changes during the infusion phase, the observed four-phase contrast dynamics could be driven by the infusion itself rather than by endogenous CSF production and flow.","tokens_in":31128,"feed_emoji":"🧠","tokens_out":6196,"duration_ms":68190,"temperature":0.7,"pith_summary":"This paper reports a method for imaging the fluid-filled spaces of a living mouse's central nervous system with synchrotron-radiation micro computed tomography (SRµCT). The method delivers whole-brain coverage at uniform voxel sizes of 6.3–8 µm and whole-organ scans in 10–32 seconds, a combination that neither multiphoton microscopy nor MRI currently offers. The authors use it to watch a barium-based contrast agent spread through the cerebrospinal fluid (CSF) over time, to quantify a roughly 37% shrinkage of the ventricles after death, and to measure cardiac-linked motion of the nasopharynx plus slow drifting of the choroid plexus. The point is that SRµCT can supply organ-wide, micrometer-resolution, time-resolved data on CSF dynamics that have so far been unavailable, providing a way to test models of solute transport in the brain.","feed_headline":"Whole-brain CSF imaging in living mice reaches 6.3 µm","feed_subtitle":"Synchrotron micro-CT maps fluid spaces in 10-second scans, bridging the gap between microscopy and MRI.","key_machinery":"The load-bearing instrument is the intravital SRµCT setup: a modular, 3D-printed radio-transparent mouse holder with multi-point fixation and heating, coupled to beamline cameras and monochromators that tune hard X-ray energy to the contrast agent's K-edge and record 5–15 ms exposures, so a full tomogram takes 10–32 s. Around this, the authors build remote physiological monitoring (temperature, oxygenation, end-tidal CO2, ECG), optional ventilation-cardiac synchronization, retrospective cardiac gating, and quantitative calibration that maps reconstructed linear attenuation coefficients to contrast-agent concentration. This combination is what makes whole-organ, micrometer-scale, time-resolved imaging of moving fluid spaces possible in a living mouse.","core_discovery":"The central claim is that intravital SRµCT can image mouse CNS fluid spaces at micrometer resolution with whole-brain field of view while the animal is alive. Using a portable, radio-transparent heated holder and fast monochromatic hard X-ray acquisitions, the authors achieved uniform 6.3 µm voxel imaging of the entire brain and resolved the ventricles, choroid plexus, and cranial and spinal subarachnoid spaces, with contrast-to-noise ratio rising from 0.2 to 7.9 after infusion of a barium nanoparticle agent. They calibrated reconstructed attenuation coefficients to barium concentration and mapped the four-phase spread and clearance of contrast agent after intraventricular and intracisternal infusions. They also showed that ventricular volume falls by about 37% within minutes of euthanasia, that the cardiac cycle deforms the nasopharynx by about 8 µm, and that the choroid plexus moves tens of microns over minutes. Taken together, these demonstrations establish SRµCT as a bridge between multiphoton microscopy and MRI for in vivo mouse brain imaging.","pith_inferences":["If intracranial pressure is not monitored, the 1–5.75 µl infusions used here could themselves alter CSF volume and pressure; a testable extension is to record ICP during infusion and compare the observed four-phase dynamics against pressure-matched controls.","The peri-mortem shrinkage result implies published ventricular volumes from ex vivo µCT or histology of the same mouse strains may carry a systematic bias, which could be corrected with a live-to-post-mortem conversion factor.","With faster detectors and tighter gating, the method could resolve whether arterial pulsations drive brain motion in mice, a question the paper leaves open because no cyclic ventricular-wall displacement was detected.","The quantitative concentration maps could seed inverse models of CSF advection-diffusion, since they provide whole-field boundary data that point measurements cannot."],"forward_implications":["CSF solute transport can be mapped over the entire brain at sub-minute temporal resolution, providing volumetric data to validate or refute computational models of CSF flow and clearance.","The two infusion routes (lateral ventricle and cisterna magna) produce distinct concentration dynamics, so SRµCT can distinguish local infusion-dominated transport from later diffusion- and convection-driven spread.","Because ventricular volume drops by about 37% shortly after death, quantitative anatomy derived from ex vivo or post-mortem imaging may systematically underestimate live CSF space dimensions.","Retrospective cardiac gating resolves tissue motion tied to the cardiac cycle, such as the roughly 8 µm nasopharyngeal deformation, and can be extended to search for cardiac-driven brain motion in mice.","Native-state acquisitions can delineate major CSF compartments without contrast agent or surgery, offering a minimally perturbing baseline for physiological studies."],"supporting_citations":[{"why":"Supplies the propagation-based phase-retrieval filter used to denoise native-state images and enhance fluid–tissue contrast.","marker":"50"},{"why":"Provide the mouse CSF production-rate range that motivates the low infusion rates and volumes chosen to limit physiological disturbance.","marker":"53,54"},{"why":"Defines the 1-bit Fourier shell correlation threshold used to estimate effective spatial resolution of the tomograms.","marker":"57"},{"why":"Gives the cisterna magna cannulation procedure on which the intracisternal infusion experiments are based.","marker":"92"},{"why":"Supplies the retrospective cardiac-gating reconstruction approach used to resolve cardiac-phase tissue motion.","marker":"93"},{"why":"Provides the established lateral-ventricle infusion and MRI protocol whose resolution limits this method extends and whose coordinates guide cannula placement.","marker":"7"},{"why":"Open data and code repository underpinning the claim that the setup and analysis are reproducible and portable across facilities.","marker":"49"},{"why":"Reference atlas used to define anatomical boundaries of ventricles and aqueduct in the peri-mortem volume quantification.","marker":"52"}],"fun_headline_variants":["Synchrotron micro-CT maps living mouse brain at 6.3 µm","Whole-brain CSF flow in live mice via synchrotron CT","Live brain fluid imaging with micrometer resolution","Intravital synchrotron CT bridges MRI and microscopy","6.3 µm whole-brain imaging in living mice"],"cache_read_input_tokens":3200,"weakest_assumption_plain":"The load-bearing premise is that a mouse under anesthesia, surgically fitted with a tracheal tube and CSF cannula, ventilated, and infused with up to 5.75 µl of nanoparticles still behaves like the intact living animal, so the measured solute spread and tissue motion reflect natural CSF physiology rather than preparation artifacts.","fun_headline_variants_meta":{"raw":{"variants":["Synchrotron micro-CT maps living mouse brain at 6.3 µm","Whole-brain CSF flow in live mice via synchrotron CT","Live brain fluid imaging with micrometer resolution","Intravital synchrotron CT bridges MRI and microscopy","6.3 µm whole-brain imaging in living mice"]},"model":"deepseek-v4-flash","effort":"low","cost_usd":0.000186,"raw_usage":{"total_tokens":1328,"prompt_tokens":948,"completion_tokens":380,"prompt_tokens_details":{"cached_tokens":384},"prompt_cache_hit_tokens":384,"prompt_cache_miss_tokens":564,"completion_tokens_details":{"reasoning_tokens":296}},"tokens_in":564,"tokens_out":380,"duration_ms":5000,"temperature":1.0,"reasoning_tokens":296,"cache_read_input_tokens":384,"cache_creation_input_tokens":0},"cache_creation_input_tokens":0},"created_at":"2026-08-06T20:16:13.321392+00:00","model_set":{"reader":"deepseek-v4-flash"},"falsifier":"Measure intracranial pressure continuously during and after a lateral-ventricle infusion of 1–5.75 µl at the rates used here; if CSF pressure rises substantially above the physiological range or ventricular volume changes during the infusion phase, the observed four-phase contrast dynamics could be driven by the infusion itself rather than by endogenous CSF production and flow.","supporting_citations":[],"review_version":1}